Abstract
A patient had complete left facial palsy followed by minimal residual left facial palsy for the next nine years. In anticipation of oncoming waves of new SARS-CoV-2 variants, and after due consideration, he took the BNT-162b2 vaccine. To his surprise his residual facial palsy gradually and almost entirely recovered after completing the two-dose vaccination, with no relapse up to six months’ followup. The mechanism and significance of such an off-target beneficial effect is discussed with conceptual projection into the future development.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
